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Abstract
Clinical exome sequencing is frequently used to identify gene-disrupting variants in individuals with
neurodevelopmental disorders. While splice-disrupting variants are known to contribute to these disorders, clinical
interpretation of cryptic splice variants outside of the canonical splice site has been challenging. Here, we discuss
papers that improve such detection.
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Splicing disruption in human disorders
Gene-disrupting genetic variants frequently lead to neu-
rodevelopmental disorders, including developmental
delay and autism spectrum disorder (ASD), when they
occur in one of the several hundred genes associated
with these disorders [1, 2]. Many of these variants are de
novo, observed in the affected child, but not in either
parent, and capable of mediating substantial risk for
neurodevelopmental disorders. Such variants alter the
quantity or quality of the encoded proteins, through de-
letions, premature stop codons, or missense variants. In
this commentary, we consider the impact of an add-
itional class of gene-disrupting variants that act by alter-
ing gene splicing. Three papers outline improvements in
detecting splice-disrupting variants [3–5], and applying
these methods predicts cryptic splicing variants in genes
associated with neurodevelopmental disorders in about
0.5% of cases and no controls [1, 2].
Splicing motifs and mechanisms
Splicing is a key process in eukaryotic cells. After tran-
scription, a nascent pre-mRNA must be converted into a
mature mRNA that can serve as a template for protein
translation. This involves the removal of introns from
the pre-mRNA, usually by the major spliceosome,
through splicing (Fig. 1a). Critical to this process are the
two-nucleotide “essential” or “canonical” splice sites
(CSS) at either side of exons: an “AG” motif upstream of
the acceptor site (A, also called the 3′ splice site), at po-
sitions A-1 and A-2, and a “GT” motif downstream of
the donor site (D, also called the 5′ splice site), at posi-
tions D+1 and D+2 (Fig. 1b).
Along with the CSS, other DNA features are known to
determine splicing behavior, including several motifs
representing binding targets of the small nuclear ribonu-
cleoproteins (snRNPs) that make up the major spliceo-
some. Motif analysis across exons (Fig. 1b) has identified
broader “CAG” and “AGGTAAGT” motifs at the ac-
ceptor and donor, respectively, as well as the polypyrimi-
dine tract, characterized by enrichment of thymine and
cytosine upstream of the acceptor (A-5 to A-40). Up-
stream of the polypyrimidine tract is the branch point
(A-10 to A-50, median A-25) with a “TNA” motif
(Fig. 1b). In the major spliceosome, U1 snRNPs bind to
the donor site, U2 snRNPs bind to the branch point, and
the U2AF protein binds to the polypyrimidine tract and
acceptor site [6].
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Fig. 1 Overview of the splicing region. a The spliceosome attaches to pre-mRNA as it is transcribed from DNA, removing introns and leaving an
exon junction complex upstream. The mature mRNA can migrate out of the nucleus for translation. b Motifs of the polypyrimidine tract, acceptor,
and donor, calculated from all protein-coding exons. c Odds ratios of observed and expected variant frequencies around the splice site based on
ExAC exome sequencing data in Zhang et al. [4]. Lord et al. [3] use the same ExAC data to calculate the mutability-adjusted proportion of
singletons (MAPS) across splicing regions, which is higher at nucleotides intolerant of variation. Jaganathan et al. [5] developed SpliceAI, a neural
network for predicting the impact of variants on splicing across the genome; the number of potential variants with a Δ score≥ 0.1 is shown
across splicing regions. Abbreviations: TSS, transcription start site; UTR, untranslated region; A, acceptor; D, donor; Pol II, polymerase II; Ter,
termination codon; Poly(A), polyadenylation
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Variation at canonical splice sites
Noncoding genetic variants that disrupt the CSS of crit-
ical genes are a known cause of human genetic diseases,
including neurodevelopmental disorders [1, 2]. Improper
splicing can lead to exon skipping or novel splice sites,
both of which can alter the reading frame of protein-
coding genes. Alternatively, intron retention incorporates
noncoding DNA, which often contains stop codons, into
the mature RNA. Consequently, identifying CSS variants
in genes with known disease associations is a routine prac-
tice in clinical exome sequencing, in which they are
treated as protein-truncating variants (PTVs) along with
premature stop codons or frameshift variants [7].
Out of 1863 de novo variants identified in individuals
with neurodevelopmental disorders [2], the 296 CSS var-
iants account for 16% of PTVs, 637 premature stop co-
dons account for 34%, and 930 frameshift insertions or
deletions account for 50%. To quantify the contribution
of these de novo variants to disorders, we consider the
frequency of variants in 3230 protein-coding genes that
are predicted to be “PTV-intolerant,” based on fewer
than expected PTVs in whole-exome sequencing data
from over 60,000 individuals (expressed statistically as a
probability loss-of-function intolerant (pLI) score ≥ 0.9)
[8]. Comparing differences in the rate of de novo PTVs
in these PTV-intolerant genes between cases and con-
trols [1, 2], we estimate that de novo PTVs contribute to
5% of ASD cases and 16% of developmental delay cases.
Since 16% of PTVs are in the CSS, this equates to 0.8%
of ASD cases and 2.6% of developmental delay cases due
to splicing disruption at the CSS.
Variation at cryptic splice sites
Exonic or intronic splice-disrupting variants outside of
the CSS are commonly referred to as cryptic splice vari-
ants, due to the challenge of identifying them. The below
articles focus on improving clinical interpretation of
these cryptic splice sites in neurodevelopmental disor-
ders by leveraging exome sequencing data from popula-
tion samples [3, 4] or deep learning methods [5]. Zhang
et al. [4] use exome sequencing data from over 60,000
population samples from the Exome Aggregation Con-
sortium (ExAC) [8] to assess the observed versus ex-
pected number of variants in the 10 nucleotides flanking
the acceptor and donor sites in PTV-intolerant genes.
They highlight six non-CSS nucleotides that are intoler-
ant of variation (Fig. 1c) and validate splicing dysregula-
tion in four of these (D-1, D+4, D+5, D+6) using paired
whole-genome and RNA sequencing from GTEx [9].
Such cryptic splice de novo variants were observed in
0.2% of ASD cases and 0.2% of developmental delay
cases. Lord et al. also use ExAC data [3] to highlight two
nucleotides that are intolerant of variation (D-1, D+5,
Fig. 1c). The D+5 site is also enriched for de novo
variants in cases of developmental delay in genes associ-
ated with this disorder, as was the polypyrimidine tract
when all nucleotides (A-5 to A-25) were considered to-
gether. By integrating phenotype data, they identified 18
likely diagnostic de novo variants in 7833 cases (0.2%).
Functional assessment of splicing using a minigene assay
validated six of the seven likely diagnostic variants that
were tested (86%).
Jaganathan et al., which includes the authors of this
commentary [5], describe the SpliceAI algorithm, a
neural network that predicts the impact of cryptic splice
variants based on a pre-mRNA sequence. The network,
trained on 10,000 nucleotides of human genomic se-
quence around 260,000 known splice sites from GEN-
CODE, is used to calculate the SpliceAI Δ score by
considering the difference in predicted splicing between
reference and variant sequence. Scores range from 0 to 1
with high scores more likely to alter splicing (Fig. 1c).
Assessing performance in the paired whole-genome and
RNA sequencing data from GTEx [9] identifies splicing
disruption proportional to the Δ score (i.e., 20% at 0.2;
80% at 0.8) with higher sensitivity and specificity than
prior algorithms [5]. High depth RNA-seq of ASD
patient-derived lymphoblastoid cell lines validated 21 of
28 (75%) de novo variants predicted to alter splicing (Δ
score, 0.10–0.99; median 0.58), including variants in the
ASD-associated genes TCF4 and KDM6B [2]. Of note,
analysis of GTEx also revealed widespread tissue-specific
splicing, which may lead such validation to underesti-
mate the true accuracy. An excess of de novo variants
predicted to alter splicing (Δ score ≥ 0.1) was observed
in both developmental delay and ASD, compared to con-
trols. Considering only genes previously associated with
neurodevelopmental disorders, de novo variants at cryp-
tic splice sites were observed in 23 out of 3953 ASD
cases (0.6%), 21 out of 4293 developmental delay cases
(0.5%), and none of the 2073 controls [1, 2].
Overall, SpliceAI predicts about 7-fold more cryptic
splice site variants than the other two approaches be-
cause it is not limited to specific nucleotides (e.g. D+5),
includes splice sites further from the exons, and evalu-
ates each splice site individually. Considering variants
assessed consistently between these three methods, Spli-
ceAI predicts all four “likely diagnostic” variants in Lord
et al. and 10 of the 18 variants (56%) highlighted by
Zhang et al.
With these improvements in detection [3–5], we
propose that de novo variants at cryptic splice sites iden-
tified in exome or genome sequencing of individuals
with neurodevelopmental disorders should undergo clin-
ical evaluation in a manner similar to deleterious mis-
sense variants. Such evaluation would incorporate
evidence from gene association studies, pLI scores, and
consistency of phenotype [7].
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Prevalence of splicing disruption in
neurodevelopmental disorders and therapeutic
potential
Using the SpliceAI estimates, splicing disruption by de
novo variants in PTV-intolerant genes underlies at least
1.4% of ASD cases (0.8% CSS and 0.6% cryptic, see esti-
mates above) and 3.1% of developmental delay cases (2.6%
CSS and 0.5% cryptic, see estimates above). These esti-
mates are equivalent to about 20,000 ASD cases 18 years-
of-age or below in the USA and 21,000 equivalent devel-
opmental delay cases. Inclusion of more genes (PTV-toler-
ant, noncoding), whole-genome sequencing to identify
deep intronic variants missed by exome sequencing, and
consideration of homozygous and heterozygous inherited
variation will only increase these estimates.
While splicing variants contribute to thousands of
cases of neurodevelopmental disorders, they may offer
opportunities for novel therapeutic targets. The success
of the FDA-approved antisense oligonucleotide (ASO)
Nusinersen to modify splicing behavior, resulting in life-
saving clinical improvement in patients with spinal mus-
cular atrophy [10], sets a precedent for treating central
nervous system disorders via splicing mechanisms. Such
a therapy would need to be developed specifically for
each splicing variant in most neurodevelopmental disor-
ders [11]. Key research milestones will include assessing
the fraction of splicing variation that can be rescued by
ASOs, efficient methods to design and test ASOs, and
assessment of the extent of rescue in vivo. These ap-
proaches may provide the first insights into whether
gene therapy can modify the symptoms of ASD and de-
velopmental delay, potentially providing a route to treat-
ment for thousands of individuals with splicing variants
and de-risking more complicated approaches to gene
therapy that could be applicable in larger populations.
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